Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer
Abstract Introduction To investigate the effect of adjuvant chemotherapy on long term survival in addition to hormonal therapy in the systemic treatment of hormonal receptor positive breast cancer patients. Methods All patients with primary non-metastatic hormonal receptor positive invasive lobular...
Gespeichert in:
| Veröffentlicht in: | Breast (Edinburgh) 2011-12, Vol.20 (6), p.505-509 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 509 |
|---|---|
| container_issue | 6 |
| container_start_page | 505 |
| container_title | Breast (Edinburgh) |
| container_volume | 20 |
| creator | Truin, Wilfred Voogd, Adri C Vreugdenhil, Gerard van der Sangen, Maurice J.C van Beek, Mike W.P.M Roumen, Rudi M.H |
| description | Abstract Introduction To investigate the effect of adjuvant chemotherapy on long term survival in addition to hormonal therapy in the systemic treatment of hormonal receptor positive breast cancer patients. Methods All patients with primary non-metastatic hormonal receptor positive invasive lobular (mixed) (=ILC) and invasive ductal (=IDC) breast cancer operated on between 1986 and 2007 were identified from a population based cohort. Four hundred ninety-eight patients with lobular (mixed) and sixteen hundred seventeen with ductal cancer were eligible. Both groups were divided in patients receiving adjuvant hormonal treatment with or without systemic chemotherapy. Results Overall survival was not statistically different in patients with ILC treated with adjuvant hormonal and chemotherapy compared to hormonal treatment alone (5-year survival 85.2% vs 82.8%, P = .68). In contrast, patients with IDC receiving adjuvant hormonal and chemotherapy had a significantly better overall survival compared to hormonal therapy alone (5-year survival rate 87.6% vs 80.8%, P |
| doi_str_mv | 10.1016/j.breast.2011.05.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905962437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960977611001214</els_id><sourcerecordid>905962437</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-5f23d9f5aa0802bf4ca383573a56c9dabeec308f4049faeb76f8495776f088463</originalsourceid><addsrcrecordid>eNqFkrGO1TAQRSMEYh8Lf4CQO6qEcRI7SYOEVgustBIFUFuOMyYOiR1s56H3A3w3jrJQ0FB5ijMzvvdOlr2kUFCg_M1U9B5liEUJlBbACgD2KDtRVpV5BS08zk7Qcci7puFX2bMQJgDoKt4-za5KyjmrG3rKft1ZPW9oFRKnyWhCdLP7diHOkjgiQa1RRXNGiyHshBym7SxtJGrExSXEy_VCjCWrjAZtDOSniSMZnV-cReJR4RqdJ6sLZp-T0LMMe3H8niiZdvvn2RMt54AvHt7r7Ov72y83H_P7Tx_ubt7d56rmZcyZLquh00zKJLDsda1k1VasqSTjqhtkj6iSdl1D3WmJfcN1W3csOaChbWteXWevj7mrdz82DFEsJiicZ2nRbUF0wDpe1lWTyPoglXcheNRi9WaR_iIoiD0AMYlDgtgDEMBECiC1vXpYsPULDn-b_jiegLcHgEnm2aAXQZnd_8Eks6IYnPnfhn8HqNlYo-T8HS8YJrd5mywUVIRSgPi8H8F-A5QC0JLW1W_SGLFO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>905962437</pqid></control><display><type>article</type><title>Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Truin, Wilfred ; Voogd, Adri C ; Vreugdenhil, Gerard ; van der Sangen, Maurice J.C ; van Beek, Mike W.P.M ; Roumen, Rudi M.H</creator><creatorcontrib>Truin, Wilfred ; Voogd, Adri C ; Vreugdenhil, Gerard ; van der Sangen, Maurice J.C ; van Beek, Mike W.P.M ; Roumen, Rudi M.H</creatorcontrib><description>Abstract Introduction To investigate the effect of adjuvant chemotherapy on long term survival in addition to hormonal therapy in the systemic treatment of hormonal receptor positive breast cancer patients. Methods All patients with primary non-metastatic hormonal receptor positive invasive lobular (mixed) (=ILC) and invasive ductal (=IDC) breast cancer operated on between 1986 and 2007 were identified from a population based cohort. Four hundred ninety-eight patients with lobular (mixed) and sixteen hundred seventeen with ductal cancer were eligible. Both groups were divided in patients receiving adjuvant hormonal treatment with or without systemic chemotherapy. Results Overall survival was not statistically different in patients with ILC treated with adjuvant hormonal and chemotherapy compared to hormonal treatment alone (5-year survival 85.2% vs 82.8%, P = .68). In contrast, patients with IDC receiving adjuvant hormonal and chemotherapy had a significantly better overall survival compared to hormonal therapy alone (5-year survival rate 87.6% vs 80.8%, P < .001). In the multivariate analysis however, this significance disappeared suggesting that the data are possibly too small, too unbalanced, or influenced by other confounding factors to come to definitive conclusions. Conclusions There are good reasons to consider ductal and lobular breast cancers as different entities in future studies. Patients with hormone receptor positive ILC seem to benefit differently from additional adjuvant chemotherapy to hormonal therapy as compared with patients with IDC.</description><identifier>ISSN: 0960-9776</identifier><identifier>EISSN: 1532-3080</identifier><identifier>DOI: 10.1016/j.breast.2011.05.005</identifier><identifier>PMID: 21665471</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adjuvant chemotherapy ; Aged ; Breast carcinoma ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - mortality ; Carcinoma, Lobular - drug therapy ; Carcinoma, Lobular - metabolism ; Carcinoma, Lobular - mortality ; Chemotherapy, Adjuvant ; Female ; Hematology, Oncology and Palliative Medicine ; Hormonal therapy ; Humans ; Invasive ductal carcinoma ; Invasive lobular carcinoma ; Middle Aged ; Netherlands ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Registries ; Retrospective Studies ; Survival ; Survival Analysis ; Treatment Outcome</subject><ispartof>Breast (Edinburgh), 2011-12, Vol.20 (6), p.505-509</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-5f23d9f5aa0802bf4ca383573a56c9dabeec308f4049faeb76f8495776f088463</citedby><cites>FETCH-LOGICAL-c462t-5f23d9f5aa0802bf4ca383573a56c9dabeec308f4049faeb76f8495776f088463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.breast.2011.05.005$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21665471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Truin, Wilfred</creatorcontrib><creatorcontrib>Voogd, Adri C</creatorcontrib><creatorcontrib>Vreugdenhil, Gerard</creatorcontrib><creatorcontrib>van der Sangen, Maurice J.C</creatorcontrib><creatorcontrib>van Beek, Mike W.P.M</creatorcontrib><creatorcontrib>Roumen, Rudi M.H</creatorcontrib><title>Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer</title><title>Breast (Edinburgh)</title><addtitle>Breast</addtitle><description>Abstract Introduction To investigate the effect of adjuvant chemotherapy on long term survival in addition to hormonal therapy in the systemic treatment of hormonal receptor positive breast cancer patients. Methods All patients with primary non-metastatic hormonal receptor positive invasive lobular (mixed) (=ILC) and invasive ductal (=IDC) breast cancer operated on between 1986 and 2007 were identified from a population based cohort. Four hundred ninety-eight patients with lobular (mixed) and sixteen hundred seventeen with ductal cancer were eligible. Both groups were divided in patients receiving adjuvant hormonal treatment with or without systemic chemotherapy. Results Overall survival was not statistically different in patients with ILC treated with adjuvant hormonal and chemotherapy compared to hormonal treatment alone (5-year survival 85.2% vs 82.8%, P = .68). In contrast, patients with IDC receiving adjuvant hormonal and chemotherapy had a significantly better overall survival compared to hormonal therapy alone (5-year survival rate 87.6% vs 80.8%, P < .001). In the multivariate analysis however, this significance disappeared suggesting that the data are possibly too small, too unbalanced, or influenced by other confounding factors to come to definitive conclusions. Conclusions There are good reasons to consider ductal and lobular breast cancers as different entities in future studies. Patients with hormone receptor positive ILC seem to benefit differently from additional adjuvant chemotherapy to hormonal therapy as compared with patients with IDC.</description><subject>Adjuvant chemotherapy</subject><subject>Aged</subject><subject>Breast carcinoma</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - mortality</subject><subject>Carcinoma, Lobular - drug therapy</subject><subject>Carcinoma, Lobular - metabolism</subject><subject>Carcinoma, Lobular - mortality</subject><subject>Chemotherapy, Adjuvant</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hormonal therapy</subject><subject>Humans</subject><subject>Invasive ductal carcinoma</subject><subject>Invasive lobular carcinoma</subject><subject>Middle Aged</subject><subject>Netherlands</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Registries</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0960-9776</issn><issn>1532-3080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkrGO1TAQRSMEYh8Lf4CQO6qEcRI7SYOEVgustBIFUFuOMyYOiR1s56H3A3w3jrJQ0FB5ijMzvvdOlr2kUFCg_M1U9B5liEUJlBbACgD2KDtRVpV5BS08zk7Qcci7puFX2bMQJgDoKt4-za5KyjmrG3rKft1ZPW9oFRKnyWhCdLP7diHOkjgiQa1RRXNGiyHshBym7SxtJGrExSXEy_VCjCWrjAZtDOSniSMZnV-cReJR4RqdJ6sLZp-T0LMMe3H8niiZdvvn2RMt54AvHt7r7Ov72y83H_P7Tx_ubt7d56rmZcyZLquh00zKJLDsda1k1VasqSTjqhtkj6iSdl1D3WmJfcN1W3csOaChbWteXWevj7mrdz82DFEsJiicZ2nRbUF0wDpe1lWTyPoglXcheNRi9WaR_iIoiD0AMYlDgtgDEMBECiC1vXpYsPULDn-b_jiegLcHgEnm2aAXQZnd_8Eks6IYnPnfhn8HqNlYo-T8HS8YJrd5mywUVIRSgPi8H8F-A5QC0JLW1W_SGLFO</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Truin, Wilfred</creator><creator>Voogd, Adri C</creator><creator>Vreugdenhil, Gerard</creator><creator>van der Sangen, Maurice J.C</creator><creator>van Beek, Mike W.P.M</creator><creator>Roumen, Rudi M.H</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer</title><author>Truin, Wilfred ; Voogd, Adri C ; Vreugdenhil, Gerard ; van der Sangen, Maurice J.C ; van Beek, Mike W.P.M ; Roumen, Rudi M.H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-5f23d9f5aa0802bf4ca383573a56c9dabeec308f4049faeb76f8495776f088463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adjuvant chemotherapy</topic><topic>Aged</topic><topic>Breast carcinoma</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - mortality</topic><topic>Carcinoma, Lobular - drug therapy</topic><topic>Carcinoma, Lobular - metabolism</topic><topic>Carcinoma, Lobular - mortality</topic><topic>Chemotherapy, Adjuvant</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hormonal therapy</topic><topic>Humans</topic><topic>Invasive ductal carcinoma</topic><topic>Invasive lobular carcinoma</topic><topic>Middle Aged</topic><topic>Netherlands</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Registries</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Truin, Wilfred</creatorcontrib><creatorcontrib>Voogd, Adri C</creatorcontrib><creatorcontrib>Vreugdenhil, Gerard</creatorcontrib><creatorcontrib>van der Sangen, Maurice J.C</creatorcontrib><creatorcontrib>van Beek, Mike W.P.M</creatorcontrib><creatorcontrib>Roumen, Rudi M.H</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Breast (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Truin, Wilfred</au><au>Voogd, Adri C</au><au>Vreugdenhil, Gerard</au><au>van der Sangen, Maurice J.C</au><au>van Beek, Mike W.P.M</au><au>Roumen, Rudi M.H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer</atitle><jtitle>Breast (Edinburgh)</jtitle><addtitle>Breast</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>20</volume><issue>6</issue><spage>505</spage><epage>509</epage><pages>505-509</pages><issn>0960-9776</issn><eissn>1532-3080</eissn><abstract>Abstract Introduction To investigate the effect of adjuvant chemotherapy on long term survival in addition to hormonal therapy in the systemic treatment of hormonal receptor positive breast cancer patients. Methods All patients with primary non-metastatic hormonal receptor positive invasive lobular (mixed) (=ILC) and invasive ductal (=IDC) breast cancer operated on between 1986 and 2007 were identified from a population based cohort. Four hundred ninety-eight patients with lobular (mixed) and sixteen hundred seventeen with ductal cancer were eligible. Both groups were divided in patients receiving adjuvant hormonal treatment with or without systemic chemotherapy. Results Overall survival was not statistically different in patients with ILC treated with adjuvant hormonal and chemotherapy compared to hormonal treatment alone (5-year survival 85.2% vs 82.8%, P = .68). In contrast, patients with IDC receiving adjuvant hormonal and chemotherapy had a significantly better overall survival compared to hormonal therapy alone (5-year survival rate 87.6% vs 80.8%, P < .001). In the multivariate analysis however, this significance disappeared suggesting that the data are possibly too small, too unbalanced, or influenced by other confounding factors to come to definitive conclusions. Conclusions There are good reasons to consider ductal and lobular breast cancers as different entities in future studies. Patients with hormone receptor positive ILC seem to benefit differently from additional adjuvant chemotherapy to hormonal therapy as compared with patients with IDC.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>21665471</pmid><doi>10.1016/j.breast.2011.05.005</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-9776 |
| ispartof | Breast (Edinburgh), 2011-12, Vol.20 (6), p.505-509 |
| issn | 0960-9776 1532-3080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905962437 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adjuvant chemotherapy Aged Breast carcinoma Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - mortality Carcinoma, Lobular - drug therapy Carcinoma, Lobular - metabolism Carcinoma, Lobular - mortality Chemotherapy, Adjuvant Female Hematology, Oncology and Palliative Medicine Hormonal therapy Humans Invasive ductal carcinoma Invasive lobular carcinoma Middle Aged Netherlands Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Registries Retrospective Studies Survival Survival Analysis Treatment Outcome |
| title | Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A24%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20histology%20on%20the%20effectiveness%20of%20adjuvant%20chemotherapy%20in%20patients%20with%20hormone%20receptor%20positive%20invasive%20breast%20cancer&rft.jtitle=Breast%20(Edinburgh)&rft.au=Truin,%20Wilfred&rft.date=2011-12-01&rft.volume=20&rft.issue=6&rft.spage=505&rft.epage=509&rft.pages=505-509&rft.issn=0960-9776&rft.eissn=1532-3080&rft_id=info:doi/10.1016/j.breast.2011.05.005&rft_dat=%3Cproquest_cross%3E905962437%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=905962437&rft_id=info:pmid/21665471&rft_els_id=S0960977611001214&rfr_iscdi=true |